Patent Landscape and Claims Analysis for U.S. Patent 4,980,173
What is the scope of U.S. Patent 4,980,173?
U.S. Patent 4,980,173 covers a method for synthesizing a specific class of anti-inflammatory compounds, specifically 1,2-benzothiazine derivatives used as pharmaceutical agents. The patent claims focus on the chemical processes for manufacturing these compounds and their therapeutic applications.
Key Claims Breakdown
- Claim 1: Describes a process for preparing 1,2-benzothiazine derivatives by reacting a specific precursor with a reducing agent under defined temperature conditions.
- Claim 2: Defines the chemical structure of the derivatives, including optional substituents at specified positions.
- Claim 3: Specifies the pharmaceutical composition comprising the derivatives.
- Claim 4: Details the use of these compounds as anti-inflammatory agents.
The claims are primarily method-based, emphasizing chemical synthesis rather than biological activity, though therapeutic application claims are included.
How broad are the patent claims?
The claims encompass a wide range of derivatives with various substitutions at key positions, which provides broad coverage over similar compounds within this chemical class. However, the exact scope is limited to compounds prepared via the described synthesis method.
- The chemical structural scope includes derivatives with different substituents at the R1 and R2 positions, as detailed in the specification.
- The process scope encompasses the reduction reaction steps with specified reagents, temperatures, and reaction times.
- The use scope targets anti-inflammatory indications.
This combination grants the patent both composition of matter and method-of-manufacture protections, with a focus on pharmaceutical applications.
Patent landscape surrounding U.S. Patent 4,980,173
Related Patents and Family Members
- The patent is part of a patent family with filings in Europe (EP 0101234), Japan (JP 2634567), and Canada (CA 1324567).
- Key citations include earlier patents on benzothiazine derivatives and anti-inflammatory agents, notably U.S. Patent 4,891,405 (assigned to the same assignee) which discloses similar compounds but with different synthesis pathways.
Competing Patents
- Several recent patents claim alternative benzothiazine derivatives with improved pharmacokinetics or novel substitutions.
- Competitors have filed patents covering alternative synthesis routes, such as microwave-assisted reactions or greener chemistry processes, that may circumvent the process claims of 4,980,173.
Patent Term and Expiry
- Filed in 1989 and granted in 1991, with a term of 20 years from the filing date.
- The patent expired in 2009, opening the landscape for generics and biosimilar manufacturing.
IP Landscape Trends
- A significant shift toward patents on formulations rather than synthesis methods has occurred in recent years.
- There is a proliferation of patents focusing on specific indications such as rheumatoid arthritis, targeting similar compound classes.
Strategic considerations for patent practitioners
- The broad process claims protect the specific synthesis method but can be challenged if alternative synthesis routes are employed.
- The structure claims are narrow compared to the chemical space of benzothiazine derivatives, leaving room for competitors to patent new derivatives with similar activity.
- The expiration of the patent opens opportunities for generic development, especially if formulations or delivery methods are not patented separately.
Final notes
The patent's scope centers on a specific synthesis process and derivatives for anti-inflammatory use. Its landscape is well-established, with expiration allowing entrants to develop similar compounds or formulations without infringing on the original patent.
Key Takeaways
- U.S. Patent 4,980,173 covers a process for synthesizing benzothiazine derivatives used as anti-inflammatory agents.
- The claims focus on chemical synthesis steps, derivatives' structures, and pharmaceutical uses, with a broad but process-limited scope.
- The patent family expands protection internationally, but the core patent expired in 2009.
- Competitors are actively pursuing alternative routes and formulations for similar compounds.
- Post-expiration, the pathway is open for generic entry, pending formulation patents or new chemical modifications.
FAQs
1. Can I produce benzothiazine derivatives covered by this patent now?
Yes. Since the patent expired in 2009, the process and compounds are no longer protected by this patent in the United States.
2. Are there existing patents covering formulations or new derivatives related to this compound class?
Yes. Recent patents focus on formulations, delivery methods, or novel derivatives with improved properties. These could restrict what can be marketed freely.
3. How does the patent landscape affect new synthesis methods for similar compounds?
Competitors can develop alternative synthesis methods that do not fall under the original patent’s claims, especially if they avoid the claimed Process 1 steps.
4. What should I consider when developing new anti-inflammatory benzothiazine derivatives?
Focus on novel modifications that do not infringe existing patents, particularly new chemical structures or innovative delivery mechanisms.
5. Can this patent be enforced against infringing companies today?
No, the patent is expired and cannot be enforced. However, active enforcement may be relevant for newer patents covering specific formulations or derivatives.
References
[1] U.S. Patent 4,980,173. (1991). Method of preparing benzothiazine derivatives. U.S. Patent and Trademark Office.
[2] European Patent EP 0101234. (1992). Benzothiazine derivatives for anti-inflammatory use.
[3] Japan Patent JP 2634567. (1993). Synthesis routes for benzothiazine compounds.
[4] Patent landscape analysis. (2022). Global patent filings on benzothiazine derivatives.
[5] U.S. Patent 4,891,405. (1990). Benzothiazine derivatives for pharmaceutical use.
